Jazz, Hikma Must Face Bulk Of Xyrem Antitrust Suit

By Bryan Koenig · August 28, 2024, 7:33 PM EDT

Jazz Pharmaceuticals and Hikma Pharmaceuticals appear bound for trial against most solo insurer and class action antitrust claims over alleged efforts to block generic competitors to Jazz's Xyrem narcolepsy drug, under...

To view the full article, register now.

Documents

Case Information

Case Title

In re Xyrem (Sodium Oxybate) Antitrust Litigation

Case Number

3:20-md-02966

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

December 16, 2020

Featured Stories

What Trump's Return Means For Bank Regulation: 5 Questions No Photo Available

With former President Donald Trump now projected to return to the White House, financial services attorneys are predicting the banking... (more story)

Trump's Win Expected To Pare Back Gensler's SEC Agenda No Photo Available

The reelection of President Donald Trump will bring with it many big changes to the U.S. Securities and Exchange Commission, including... (more story)

Trump Has Official Immunity. What About His Aides? No Photo Available

Whether the U.S. Supreme Court's decision on presidential immunity extends to subordinates who follow a president's orders has become ... (more story)